Trade Intellia Therapeutics Inc - NTLA CFD
What is Intellia Therapeutics Inc (NTLA)?
Intellia Therapeutics Inc is a biotechnology company focused on the development of genome editing technologies for the treatment of genetic diseases. The company specializes in the application of CRISPR/Cas9 technology to create therapies that aim to modify DNA within living cells. Intellia's research and development efforts include both in vivo and ex vivo approaches, targeting a range of genetic disorders. The company collaborates with academic institutions and industry partners to advance its pipeline and enhance the delivery mechanisms of its gene-editing platforms. Intellia Therapeutics operates within the broader field of genetic medicine, contributing to the advancement of precision therapies that seek to address the underlying causes of inherited conditions. Its work involves extensive preclinical and clinical studies to evaluate the safety and efficacy of its therapeutic candidates. The company's mission centers on leveraging innovative gene-editing tools to develop transformative treatments that have the potential to improve patient outcomes in various genetic diseases.
Intellia Therapeutics Inc Stock Price Today: Live Overview
The price today is shaped by active market conditions, with Intellia Therapeutics Inc at $15.39. Throughout the session, it has moved between $15.17 and $15.87, showing a daily change of +1.9802%.
FAQ: Intellia Therapeutics Inc (NTLA)
What is the current price of NTLA stock?
Intellia Therapeutics Inc is currently trading at $15.39.
Does NTLA pay dividends?
Intellia Therapeutics Inc does not pay dividends.
Does NTLA have a formal corporate presence or regional headquarters in the UAE?
Intellia Therapeutics Inc does not have an official office or subsidiary in the UAE and operates through partners only.
What is NTLA best known for?
Intellia Therapeutics Inc is most famous for its gene editing and CRISPR technology development.
What assets are typically shown together with NTLA?
Commonly shown alongside NTLA: Hengan, Shin-Etsu Chemical Co., Ltd., Perpetua Resources Corp
Latest shares articles



